Q2 25 EPS
$4.52
BEAT +6.33%
Est. $4.25
Q2 25 Revenue
$2.96B
BEAT +2.00%
Est. $2.91B
vs S&P Since Q2 25
-1.1%
TRAILING MARKET
VRTX +15.7% vs S&P +16.8%
Market Reaction
Did VRTX Beat Earnings? Q2 2025 Results
Vertex Pharmaceuticals posted a confident beat to open its second quarter, with non-GAAP earnings of $4.52 per share clearing the $4.25 consensus by 6.33% and revenue of $2.96 billion topping estimates by 2.00% on 12.1% year-over-year growth, adding … Read more Vertex Pharmaceuticals posted a confident beat to open its second quarter, with non-GAAP earnings of $4.52 per share clearing the $4.25 consensus by 6.33% and revenue of $2.96 billion topping estimates by 2.00% on 12.1% year-over-year growth, adding to a broader run of strong earnings across the market. The primary engine remained the cystic fibrosis franchise, where TRIKAFTA/KAFTRIO contributed $2.55 billion, while next-generation modulator ALYFTREK added $156.80 million in its first full ramp quarter following approvals in the U.S., EU, U.K., and Canada. CASGEVY and newly launched JOURNAVX provided incremental contributions as those programs build commercial momentum. The quarter was not without setbacks; VX-993 failed its Phase 2 primary endpoint in acute pain, and the FDA signaled a narrow path for broad peripheral neuropathic pain labeling. Still, Vertex reiterated its full-year 2025 revenue guidance of $11.85 billion to $12.00 billion, underpinned by continued CF growth and advancing pipeline catalysts, including povetacicept and zimislecel regulatory submissions expected in 2026.
Key Takeaways
- • Continued performance of CF therapies including TRIKAFTA/KAFTRIO
- • Early contributions from ALYFTREK, CASGEVY, and JOURNAVX launches
- • Strong U.S. patient demand and favorable gross-to-net dynamics versus prior year
- • Strong performance across multiple geographies outside the U.S.
VRTX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
VRTX Revenue by Segment
With YoY comparisons, source: SEC Filings
VRTX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Vertex delivered a strong quarter of revenue growth with each of our three product launches — ALYFTREK, JOURNAVX, and CASGEVY — contributing, as well as continued advancement of our clinical programs. As we enter the second half of the year, we are focused on expanding leadership in cystic fibrosis, executing the launches, advancing the pipeline, and preparing for submissions and commercialization in additional disease areas.”
— Reshma Kewalramani, Q2 2025 Earnings Press Release
VRTX Earnings Trends
VRTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
VRTX EPS Trend
Earnings per share: estimate vs actual
VRTX Revenue Trend
Quarterly revenue: estimate vs actual
VRTX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $4.31 | $4.47 | +3.81% | $2.99B | -0.36% |
| Q4 25 MISS FY | $5.15 | $5.03 | -2.30% | $3.19B | +0.48% |
| FY Full Year | — | $18.40 | — | $12.00B | — |
| Q3 25 BEAT | $4.58 | $4.80 | +4.87% | $3.08B | +0.56% |
| Q2 25 BEAT | $4.25 | $4.52 | +6.33% | $2.96B | +2.00% |
| Q1 25 MISS | $4.29 | $4.06 | -5.44% | $2.77B | -3.17% |